The Social Amoeba Dictyostelium discoideum Is Highly Resistant to Polyglutamine Aggregation.

The Journal of Biological Chemistry
Stephanie SantarriagaKenneth Matthew Scaglione

Abstract

The expression, misfolding, and aggregation of long repetitive amino acid tracts are a major contributing factor in a number of neurodegenerative diseases, including C9ORF72 amyotrophic lateral sclerosis/frontotemporal dementia, fragile X tremor ataxia syndrome, myotonic dystrophy type 1, spinocerebellar ataxia type 8, and the nine polyglutamine diseases. Protein aggregation is a hallmark of each of these diseases. In model organisms, including yeast, worms, flies, mice, rats, and human cells, expression of proteins with the long repetitive amino acid tracts associated with these diseases recapitulates the protein aggregation that occurs in human disease. Here we show that the model organism Dictyostelium discoideum has evolved to normally encode long polyglutamine tracts and express these proteins in a soluble form. We also show that Dictyostelium has the capacity to suppress aggregation of a polyglutamine-expanded Huntingtin construct that aggregates in other model organisms tested. Together, these data identify Dictyostelium as a novel model organism with the capacity to suppress aggregation of proteins with long polyglutamine tracts.

References

Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·S Krobitsch, S Lindquist
Feb 22, 2000·The Journal of Biological Chemistry·A Garay-ArroyoA A Covarrubias
Jun 12, 2002·The Journal of Cell Biology·Anatoli B MeriinMichael Y Sherman
May 6, 2005·Nature·L EichingerA Kuspa
Apr 10, 2007·Annual Review of Neuroscience·Harry T Orr, Huda Y Zoghbi
Jun 5, 2007·Nature Protocols·Petra FeyRex L Chisholm
Oct 24, 2007·PLoS Genetics·Julide Bilen, Nancy M Bonini
May 17, 2008·Development, Growth & Differentiation·Hideko Urushihara
Sep 6, 2008·Plant Physiology·Marina BattagliaAlejandra A Covarrubias
Sep 10, 2008·Trends in Neurosciences·Aislinn J Williams, Henry L Paulson
Oct 30, 2008·The Journal of Biological Chemistry·J Lawrence MarshLeslie Michels Thompson
Oct 23, 2009·The Biochemical Journal·Margit FuchsJacques Landry
May 21, 2010·Proceedings of the National Academy of Sciences of the United States of America·Amy L RobertsonStephen P Bottomley
Sep 2, 2011·Cold Spring Harbor Protocols·Daniel R RinesPeter K Sorger
Sep 13, 2011·International Review of Neurobiology·Zhenming Yu, Nancy M Bonini
Sep 5, 2012·Molecular Neurobiology·Pawel M SwitonskiMaciej Figiel
May 31, 2013·Methods in Molecular Biology·Martin L Duennwald
May 1, 1989·Plant Molecular Biology·L DureZ R Sung
May 17, 2014·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Richard I Morimoto, Ana Maria Cuervo
Jun 21, 2014·Trends in Cell Biology·Mark S HippF Ulrich Hartl
Aug 6, 2014·Proceedings of the National Academy of Sciences of the United States of America·Can KayatekinSusan Lindquist
Dec 10, 2014·Proceedings of the National Academy of Sciences of the United States of America·Leslie RipaudMark S Hipp
May 6, 2015·Proceedings of the National Academy of Sciences of the United States of America·Liliana MalinovskaSimon Alberti
Jun 19, 2015·Scientific Reports·Amber Petersen, Nashaat Z Gerges

❮ Previous
Next ❯

Citations

Oct 23, 2016·Biochimica Et Biophysica Acta. General Subjects·Robert J Huber, Danton H O'Day
Nov 4, 2016·G3 : Genes - Genomes - Genetics·Michelle D LeachLeah E Cowen
Jul 29, 2020·International Journal of Molecular Sciences·Lieselotte ErberMario Mörl
Apr 4, 2021·International Journal of Molecular Sciences·Valentina Brandi, Fabio Polticelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating genetic alterations in this genetically heterogeneous disorder.

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Related Papers

Human Molecular Genetics
John Douglas Cleary, Laura P W Ranum
Current Opinion in Genetics & Development
John Douglas Cleary, Laura P W Ranum
Movement Disorders : Official Journal of the Movement Disorder Society
Seán O'DowdTimothy Lynch
© 2021 Meta ULC. All rights reserved